Acadian Asset Management’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-110,882
| Closed | -$3.21M | – | 2172 |
|
|
2025
Q4 | $3.21M | Sell |
110,882
-31,478
| -22% | -$598K | 0.01% | 778 |
|
|
2025
Q3 | $1.1M | Buy |
142,360
+24,149
| +20% | +$181K | ﹤0.01% | 1029 |
|
|
2025
Q2 | $873K | Sell |
118,211
-1,375
| -1% | -$12.1K | ﹤0.01% | 1006 |
|
|
2025
Q1 | $1.03M | Buy |
+119,586
| New | +$1.85M | ﹤0.01% | 931 |
|
|
2024
Q4 | – | Sell |
-976
| Closed | -$46K | – | 1975 |
|
|
2024
Q3 | $46K | Sell |
976
-1,884
| -66% | -$83.1K | ﹤0.01% | 1814 |
|
|
2024
Q2 | $143K | Sell |
2,860
-15,897
| -85% | -$1.15M | ﹤0.01% | 1487 |
|
|
2024
Q1 | $2.1M | Buy |
18,757
+11,725
| +167% | +$1.17M | 0.01% | 648 |
|
|
2023
Q4 | $407K | Sell |
7,032
-7,131
| -50% | -$287K | ﹤0.01% | 1072 |
|
|
2023
Q3 | $449K | Buy |
+14,163
| New | +$673K | ﹤0.01% | 1030 |
|
|
2020
Q3 | – | Sell |
-5,154
| Closed | -$3.02M | – | 2292 |
|
|
2020
Q2 | $3.02M | Sell |
5,154
-2,722
| -35% | -$929K | 0.01% | 617 |
|
|
2020
Q1 | $1.15M | Buy |
7,876
+2,692
| +52% | +$470K | 0.01% | 752 |
|
|
2019
Q4 | $742K | Buy |
5,184
+1,120
| +28% | +$81.9K | ﹤0.01% | 962 |
|
|
2019
Q3 | $160K | Buy |
4,064
+2,051
| +102% | +$149K | ﹤0.01% | 1374 |
|
|
2019
Q2 | $204K | Buy |
+2,013
| New | +$237K | ﹤0.01% | 1224 |
|
|
2018
Q2 | – | Sell |
-443
| Closed | -$175K | – | 1790 |
|
|
2018
Q1 | $175K | Buy |
+443
| New | +$175K | ﹤0.01% | 1091 |
|
Other funds holding MRSN
Acadian Asset Management's MRSN Position: Q1 2026 in Review
Acadian Asset Management sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 110,882 shares — an estimated $3.21M sold.
Acadian Asset Management first reported a position in MRSN in Q1 2018 and held it in 15 quarters. The position peaked at $3.21M in Q4 2025. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Acadian Asset Management reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Acadian Asset Management sold 110,882 Mersana Therapeutics shares in Q1 2026, an estimated $3.21M.
- Acadian Asset Management first reported a position in Mersana Therapeutics in Q1 2018 and held it in 15 quarters.
- Acadian Asset Management's Mersana Therapeutics position peaked at $3.21M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.